A randomised, double-blind, placebo-controlled, parallel group trial evaluating safety, tolerability, pharmacodynamics and pharmacokinetics of BI 1291583 one tablet once daily over 12 weeks versus placebo in adult patients with cystic fibrosis bronchiectasis (ClairaflyTM)
Status: Ongoing
Details
This study is being done to test the study drug, BI 1291583, for safety and side effects,
when compared to a placebo, in subjects who have cystic fibrosis with bronchiectasis
(CFB).
Sponsor: Sponsor: Boehringer Ingelheim Pharmaceuticals, Inc.
NCT05865886 - IRB# 2023-162